News from all angles
(MedPage Today) -- The FDA on Friday approved injectable gefurulimab (Klygefa), a dual-binding nanobody that blocks complement component 5 (C5) activation, to treat generalized myasthenia gravis in a…
Redirecting to MedPage Today in 3 seconds...
Share this story with your network